Financhill
Sell
48

BBIO Quote, Financials, Valuation and Earnings

Last price:
$33.79
Seasonality move :
-4.32%
Day range:
$33.76 - $34.90
52-week range:
$21.62 - $41.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
28.29x
P/B ratio:
--
Volume:
2.7M
Avg. volume:
2.3M
1-year change:
-8.45%
Market cap:
$6.4B
Revenue:
$9.3M
EPS (TTM):
-$2.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BBIO
BridgeBio Pharma
$4M -$1.09 2390.78% -3.13% $49.43
ALNY
Alnylam Pharmaceuticals
$582.2M -$0.14 31.49% -80.37% $298.97
CPRX
Catalyst Pharmaceuticals
$133.6M $0.55 20.93% 70.76% $33.00
PFE
Pfizer
$17.3B $0.46 27.51% 12.4% $31.18
REGN
Regeneron Pharmaceuticals
$3.8B $11.21 9.55% 7.9% $1,005.61
SAVA
Cassava Sciences
-- -$0.68 -- -28% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BBIO
BridgeBio Pharma
$33.79 $49.43 $6.4B -- $0.00 0% 28.29x
ALNY
Alnylam Pharmaceuticals
$246.27 $298.97 $31.8B -- $0.00 0% 14.90x
CPRX
Catalyst Pharmaceuticals
$22.78 $33.00 $2.7B 19.31x $0.00 0% 6.03x
PFE
Pfizer
$26.30 $31.18 $149B 35.54x $0.42 6.39% 2.52x
REGN
Regeneron Pharmaceuticals
$681.58 $1,005.61 $74.9B 16.87x $0.00 0% 5.67x
SAVA
Cassava Sciences
$2.75 -- $132.3M -- $0.00 0% 3.02x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BBIO
BridgeBio Pharma
351.32% 1.769 35.65% 1.92x
ALNY
Alnylam Pharmaceuticals
96.94% 1.172 2.89% 2.57x
CPRX
Catalyst Pharmaceuticals
-- 0.881 -- 4.75x
PFE
Pfizer
41.92% 0.489 40.56% 0.64x
REGN
Regeneron Pharmaceuticals
6.34% 1.263 1.71% 4.34x
SAVA
Cassava Sciences
-- -3.226 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BBIO
BridgeBio Pharma
$2.1M -$187.1M -80.46% -- -5168.12% -$182.3M
ALNY
Alnylam Pharmaceuticals
$415M -$76.9M -36.66% -- -14.83% $39.5M
CPRX
Catalyst Pharmaceuticals
$109.4M $50.9M 27.81% 27.81% 39.56% $72.6M
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B
REGN
Regeneron Pharmaceuticals
$3.2B $1.2B 16.02% 17.19% 40.5% $1B
SAVA
Cassava Sciences
-- -$30.6M -- -- -- -$18.3M

BridgeBio Pharma vs. Competitors

  • Which has Higher Returns BBIO or ALNY?

    Alnylam Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of -22.27%. BridgeBio Pharma's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    ALNY
    Alnylam Pharmaceuticals
    82.85% -$0.87 $1.1B
  • What do Analysts Say About BBIO or ALNY?

    BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 46.28%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $298.97 which suggests that it could grow by 21.4%. Given that BridgeBio Pharma has higher upside potential than Alnylam Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    ALNY
    Alnylam Pharmaceuticals
    11 8 1
  • Is BBIO or ALNY More Risky?

    BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.841%.

  • Which is a Better Dividend Stock BBIO or ALNY?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or ALNY?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $500.9M. BridgeBio Pharma's net income of -$162M is lower than Alnylam Pharmaceuticals's net income of -$111.6M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 28.29x versus 14.90x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    28.29x -- $2.7M -$162M
    ALNY
    Alnylam Pharmaceuticals
    14.90x -- $500.9M -$111.6M
  • Which has Higher Returns BBIO or CPRX?

    Catalyst Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 34.1%. BridgeBio Pharma's return on equity of -- beat Catalyst Pharmaceuticals's return on equity of 27.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    CPRX
    Catalyst Pharmaceuticals
    85.02% $0.35 $660.9M
  • What do Analysts Say About BBIO or CPRX?

    BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 46.28%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 44.86%. Given that BridgeBio Pharma has higher upside potential than Catalyst Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    CPRX
    Catalyst Pharmaceuticals
    6 0 0
  • Is BBIO or CPRX More Risky?

    BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.

  • Which is a Better Dividend Stock BBIO or CPRX?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or CPRX?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $128.7M. BridgeBio Pharma's net income of -$162M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 28.29x versus 6.03x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    28.29x -- $2.7M -$162M
    CPRX
    Catalyst Pharmaceuticals
    6.03x 19.31x $128.7M $43.9M
  • Which has Higher Returns BBIO or PFE?

    Pfizer has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 25.23%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About BBIO or PFE?

    BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 46.28%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 18.54%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    PFE
    Pfizer
    7 13 1
  • Is BBIO or PFE More Risky?

    BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

  • Which is a Better Dividend Stock BBIO or PFE?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.39% to investors and pays a quarterly dividend of $0.42 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or PFE?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Pfizer quarterly revenues of $17.7B. BridgeBio Pharma's net income of -$162M is lower than Pfizer's net income of $4.5B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 28.29x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    28.29x -- $2.7M -$162M
    PFE
    Pfizer
    2.52x 35.54x $17.7B $4.5B
  • Which has Higher Returns BBIO or REGN?

    Regeneron Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 36.03%. BridgeBio Pharma's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
  • What do Analysts Say About BBIO or REGN?

    BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 46.28%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,005.61 which suggests that it could grow by 47.55%. Given that Regeneron Pharmaceuticals has higher upside potential than BridgeBio Pharma, analysts believe Regeneron Pharmaceuticals is more attractive than BridgeBio Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    REGN
    Regeneron Pharmaceuticals
    11 7 0
  • Is BBIO or REGN More Risky?

    BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

  • Which is a Better Dividend Stock BBIO or REGN?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or REGN?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. BridgeBio Pharma's net income of -$162M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 16.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 28.29x versus 5.67x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    28.29x -- $2.7M -$162M
    REGN
    Regeneron Pharmaceuticals
    5.67x 16.87x $3.7B $1.3B
  • Which has Higher Returns BBIO or SAVA?

    Cassava Sciences has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Cassava Sciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    SAVA
    Cassava Sciences
    -- -$0.58 --
  • What do Analysts Say About BBIO or SAVA?

    BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 46.28%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4118.18%. Given that Cassava Sciences has higher upside potential than BridgeBio Pharma, analysts believe Cassava Sciences is more attractive than BridgeBio Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    SAVA
    Cassava Sciences
    0 2 0
  • Is BBIO or SAVA More Risky?

    BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.985, suggesting its less volatile than the S&P 500 by 198.512%.

  • Which is a Better Dividend Stock BBIO or SAVA?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or SAVA?

    BridgeBio Pharma quarterly revenues are $2.7M, which are larger than Cassava Sciences quarterly revenues of --. BridgeBio Pharma's net income of -$162M is lower than Cassava Sciences's net income of -$27.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 28.29x versus 3.02x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    28.29x -- $2.7M -$162M
    SAVA
    Cassava Sciences
    3.02x -- -- -$27.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is AT&T Stock Dropping?
Why Is AT&T Stock Dropping?

The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…

Is American Express Stock Going Lower?
Is American Express Stock Going Lower?

American Express Company (NYSE:AXP) has long been a Buffett favorite…

Cigna vs Costco Stock: Which Is Best?
Cigna vs Costco Stock: Which Is Best?

Cigna and Costco don’t usually go hand in hand but…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
45
QMCO alert for Jan 18

Quantum [QMCO] is down 15.61% over the past day.

Buy
51
QRVO alert for Jan 18

Qorvo [QRVO] is up 14.47% over the past day.

Sell
31
ATEX alert for Jan 18

Anterix [ATEX] is up 11.14% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock